Why CareDx, Inc.’s (CDNA) Stock Is Up 20.85%
As of Friday, October 30, CareDx, Inc.’s CDNA share price has surged by 20.85%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Commentary & Analysis
Which Is a Better Investment, CareDx, Inc. or Vir Biotechnology, Inc. Stock?
Learn more about whether CareDx, Inc. or Vir Biotechnology, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
What You Need to Know About CareDx, Inc.'s Q4 Earnings
CareDx, Inc.'s fiscal Q4 earnings report was released on Thursday, October 29. Let's dive in to see if (CDNA) missed or beat analyst's expectations.Tudor Pop
Why CareDx, Inc.’s (CDNA) Stock Is Up 5.38%
As of Monday, October 19, CareDx, Inc.’s CDNA share price has surged by 5.38%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why CareDx, Inc.’s (CDNA) Stock Is Down 5.01%
As of Tuesday, October 06, CareDx, Inc.’s CDNA share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | CDNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,508.2 | $227.3 | 66% |
|
| Shares Out (Mil) | 55.0 | 53.4 | 50% |
|
| Institutional Ownership | 95.8% | 92.9% | 68% |
|
| Float (Mil) | 50.8 | 41.4 | 47% |
|
| Beta | 2.38 | 0.95 | 95% |
|
| Avg Daily Volume (000s) | 1,489 | 468 | 76% |
|
| Price Change (52-week) |
480.9% | 47.4% | 100% |
|
| Growth | CDNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 14.6% | 13.2% | 72% |
|
| Net Income (5yr) | (2.7%) | (10.1%) | 36% |
|
| EPS (5yr) | 0.1% | 15.8% | 31 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (19.6%) | (15.7%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | $0.363 | $1.782 | $1.578 | |
| Month Ago EPS | $0.232 | $1.198 | $1.290 | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.253 | $1.213 | $1.355 | |
| Year/Year Chg | 3.7% | (544.4%) | (656.1%) | |
| Financials | CDNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $497 | $37 | 41% |
|
| Net Income (TTM) (Mil) | $129 | ($44) | 63% |
|
| EPS (TTM) | $2.499 | ($1.600) | 75% |
|
| Operating Cash Flow (TTM) (Mil) | $69 | ($34) | 49% |
|
| Net Cash Flow (TTM) (Mil) | $160 | $1 | 81% |
|
| Long-Term Debt (Q1) (Mil) | $20 | $4 | 33% |
|
| Enterprise Value (Q1) (Mil) | $4,371 | $174 | 61% |
|
| Valuation | CDNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.63 | 2.14 | 91% |
|
| P/E | 35.6 | 20.6 | 76% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 355.9 | 1.1 | 100% |
|
| Ratios | CDNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 71.0% | 66.5% | 82% |
|
| Net Margin | 25.9% | (69.8%) | 84% |
|
| ROA | 24.0% | (47.1%) | 97% |
|
| ROE | 33.0% | (52.0%) | 89% |
|
| Liabilities to Assets | 27.1% | 29.7% | 19% |
|
| F-Score | 6 | 2 | 67% |
|
CareDx, Inc. did not pass any screens on 11/4/2026.
